Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.17925/EE.2016.12.01.31 http://scihub22266oqcxt.onion/10.17925/EE.2016.12.01.31 C5813455!5813455!29632584     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Endocrinol 2016 ; 12 (1): 31-2 Nephropedia Template TP {{tp|p=29632584|t=2016. Cardiovascular Outcomes with Empagliflozin ? News for Type 2 Diabetes Therapy |pdf=|usr=}}{{29632584}} gab.com Text Cardiovascular Outcomes with Empagliflozin News for Type 2 Diabetes Therapy JO: Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29632584 #FOAvip Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard treatment with regard to a combined cardiovascular primary endpoint, empagliflozin showed superiority with a significantly lower incidence of cardiovascular events. Twit Text FOAVip Cardiovascular Outcomes with Empagliflozin News for Type 2 Diabetes Therapy ????Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29632584 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29632584 #FOAvip English Wikipedia <ref>{{Cite pmid|29632584}}</ref> Cardiovascular Outcomes with Empagliflozin ? News for Type 2 Diabetes Therapy #MMPMID29632584 Gallwitz B Eur Endocrinol 2016[Mar]; 12 (1): 31-2 PMID29632584show ga Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard treatment with regard to a combined cardiovascular primary endpoint, empagliflozin showed superiority with a significantly lower incidence of cardiovascular events. äCardiovascular Outcomes with Empagliflozin ? News for Type 2 Diabetes (epmc).pdf DeepDyve Pubget Overpricing